# 4BIO Capital

> 4BIO Capital is a VC fund in London backing Biotechnology and Health Care. See 32 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 32
- Last investment: May 2026
- Lead investor: 44%
- Fund size: $50M
- Last fund: Sep 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/4bio-capital-partners
- X (Twitter): https://twitter.com/4biocapital
- Website: http://www.4biocapital.com

4BIO Capital is a VC fund in London focused on Biotechnology and Health Care. 4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.

## Contacts

5 contacts available for 4BIO Capital. Shizune tracks 6 team members at 4BIO Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/4bio-capital-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $5M–$19M |
| Series A | $24M–$94M |
| Series B | $12M–$125M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 47% |
| Health Care | 9 | 28% |
| Therapeutics | 9 | 28% |
| Medical | 8 | 25% |
| Life Science | 5 | 16% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 31% |
| Seed | 5 | 16% |
| Series B | 4 | 13% |
| Post-IPO Equity | 3 | 9% |
| Series C | 2 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 22% |
| United Kingdom | 7 | 22% |
| France | 2 | 6% |
| Switzerland | 2 | 6% |
| Japan | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew Kozlov | Managing Partner | 2 | https://shizune.co/investors/profile/andrey-kozlov |
| Dmitry Kuzmin | Managing Partner | 8 | https://shizune.co/investors/profile/dmitry-kuzmin |
| Kieran Mudryy | Partner | 1 | https://shizune.co/investors/profile/kieran-mudryy |
| Owen Smith | Principal | 7 | https://shizune.co/investors/profile/owen-smith-b474 |
| Vasily Fedorin | Principal | 0 | https://shizune.co/investors/profile/vasily-fedorin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cytospire Therapeutics | Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M | Series A | May 05, 2026 |  |
| Ray Therapeutics | Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $125M | Series B | Apr 21, 2026 |  |
| Trogenix | Trogenix operates as a therapeutics company, that treats aggressive cancers. | $94.4M | Series A | Oct 06, 2025 |  |
| Actithera | Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M | Series A | Jul 09, 2025 |  |
| March Biosciences | March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M | Series A | Oct 23, 2024 |  |
| Hornet Therapeutics | Hornet Therapeutics provides immune cell metabolism & cell therapy for cancer treatment. | $5M | Seed | May 23, 2024 |  |
| Trogenix | Trogenix operates as a therapeutics company, that treats aggressive cancers. | $19.1M | Seed | Jan 01, 2024 |  |
| ViaNautis | Precision Solutions | $24.6M | Series A | Nov 13, 2023 |  |
| Ray Therapeutics | Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $100M | Series A | May 16, 2023 |  |
| Ascend Gene & Cell Therapies | Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form. | $65.9M | Series A | Mar 20, 2023 |  |

10 of 32 investments shown.

## Co-investors
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 7 deals together
- [Fast Track Initiative, Inc.](https://shizune.co/investors/profile/fast-track-initiative) — VC Fund, 6 deals together
- [Nippon Venture Capital](https://shizune.co/investors/profile/nippon-venture-capital) — VC Fund, 6 deals together
- [MRL Ventures Fund](https://shizune.co/investors/profile/mrl-venture-fund) — VC Fund, 5 deals together
- [UPMC Enterprises](https://shizune.co/investors/profile/upmc-enterprises) — VC Fund, 5 deals together
- [DCVC Bio](https://shizune.co/investors/profile/dcvc-bio) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Investinor](https://shizune.co/investors/profile/investinor) — VC Fund
- [Skyfall Ventures](https://shizune.co/investors/profile/skyfall-ventures) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Medical Investors in Norway](https://shizune.co/investors/medical-investors-norway)
- [Medical VC Funds in Norway](https://shizune.co/investors/medical-vc-funds-norway)
- [Biotechnology Investors in Norway](https://shizune.co/investors/biotechnology-investors-norway)
- [Biotech Investors in Norway](https://shizune.co/investors/biotech-investors-norway)

## FAQ

### What does 4BIO Capital invest in?

4BIO Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is 4BIO Capital's check size?

4BIO Capital typically joins rounds of $5M–$19M at Seed, $24M–$94M at Series A and $12M–$125M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 4BIO Capital participates in.

### How do I contact 4BIO Capital?

Public channels for 4BIO Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 4BIO Capital?

The team at 4BIO Capital includes Andrew Kozlov (Managing Partner), Dmitry Kuzmin (Managing Partner) and Kieran Mudryy (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co